We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
Novavax (NVAX - Free Report) ended the recent trading session at $8.67, demonstrating a +1.17% change from the preceding day's closing price. This change outpaced the S&P 500's 0.41% gain on the day. At the same time, the Dow added 0.18%, and the tech-heavy Nasdaq gained 0.31%.
Shares of the vaccine maker have appreciated by 14.73% over the course of the past month, outperforming the Medical sector's loss of 0.38%, and the S&P 500's gain of 3.15%.
Investors will be eagerly watching for the performance of Novavax in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.26, signifying a 65.79% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $67 million, showing a 20.72% drop compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.68 per share and revenue of $1.03 billion, indicating changes of +317.89% and +51.52%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novavax. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Novavax is currently sporting a Zacks Rank of #3 (Hold).
In the context of valuation, Novavax is at present trading with a Forward P/E ratio of 3.2. This valuation marks a discount compared to its industry average Forward P/E of 18.79.
We can additionally observe that NVAX currently boasts a PEG ratio of 0.11. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.68 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 78, positioning it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider
Novavax (NVAX - Free Report) ended the recent trading session at $8.67, demonstrating a +1.17% change from the preceding day's closing price. This change outpaced the S&P 500's 0.41% gain on the day. At the same time, the Dow added 0.18%, and the tech-heavy Nasdaq gained 0.31%.
Shares of the vaccine maker have appreciated by 14.73% over the course of the past month, outperforming the Medical sector's loss of 0.38%, and the S&P 500's gain of 3.15%.
Investors will be eagerly watching for the performance of Novavax in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.26, signifying a 65.79% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $67 million, showing a 20.72% drop compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.68 per share and revenue of $1.03 billion, indicating changes of +317.89% and +51.52%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novavax. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Novavax is currently sporting a Zacks Rank of #3 (Hold).
In the context of valuation, Novavax is at present trading with a Forward P/E ratio of 3.2. This valuation marks a discount compared to its industry average Forward P/E of 18.79.
We can additionally observe that NVAX currently boasts a PEG ratio of 0.11. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.68 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 78, positioning it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.